FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”

One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment